Telesis bio announces licensing agreement with regeneron to adopt gibson sola™ platform for rapid on-site dna and gene synthesis

San diego--(business wire)--telesis bio inc. (otcmkts: tbio), a leading provider of dna and mrna synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with regeneron pharmaceuticals, inc. to deploy telesis bio's revolutionary gibson sola™ platform at its r&d core facilities. this will help regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. using gibson sola at s.
REGN Ratings Summary
REGN Quant Ranking